Arrowhead Pharmaceuticals' Plozasiran Enters FDA STAR Pilot Program for Severe Hypertriglyceridemia

The U.S. Food and Drug Administration (FDA) has granted Arrowhead Pharmaceuticals' plozasiran entry into the Split Real Time Application Review (STAR) pilot program. This program aims to expedite the review process for the supplemental new drug application (sNDA) for plozasiran in severe hypertriglyceridemia (sHTG, a condition that significantly increases the risk of acute pancreatitis).